Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15450

    +

    P3.04-068 - A Genetic Variation in a microRNA Target Site of ETS2 Gene Is Associated with Clinical Outcome of Chemotherapy in Non-Small Cell Lung Cancer (ID 2904)

    09:30 - 09:30  |  Author(s): D.K. Jung
    • Abstract
    • Slides

    Background:
    Genetic polymorphisms in miRNAs or their target sites may affect miRNA-mRNA interactions, leading to altered expression of target genes. Recently, crosslinking, ligation, and sequencing of hybrids (CLASH) provided direct observation of transcriptome-wide miRNA-target pairs. The present study was performed to investigate the association of single nucleotide polymorphisms (SNPs) located in the miRNA target sites, which were experimentally verified by CLASH, with the clinical outcome of chemotherapy in advanced non–small cell lung cancer (NSCLC).
    
    Methods:
    Ninety eight SNPs in miRNA target sites of cancer related genes were selected from 18,500 miRNA:target interactions in CLASH data, and investigated in 384 advanced NSCLC patients who received first-line paclitaxel-cisplatin chemotherapy, using a sequenom mass spectrometry-based genotype assay.
    
    Results:
    Of the 98 SNPs analyzed, 17 SNPs were significantly associated with the clinical outcome after chemotherapy. Among these, ANAPC1 rs3814026C>T, ETS2 rs461155A>G, and SORBS1 rs7081076C>A were found to be associated with both chemotherapy response and survival. Notably, the relative expression level of ETS2 was significantly associated with rs461155A>G genotypes in both tumor and paired normal lung tissues (Ptrend = 4 x 10[-7], and 0.0003, respectively).
    
    Conclusion:
    These findings suggest that the three SNPs, especially ETS2 rs461155A>G, could be used as biomarkers predicting the response and survival of NSCLC patients treated with first-line paclitaxel-cisplatin chemotherapy.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.